Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Rizzo

Showing results (251-260 of 381) with videos related to

Pageof 39
Sort By:
Future Oncology (London, England)|February 3, 2022
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, et al.
Scientific Reports|July 4, 2018
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of conceptStefania De Lorenzo, Francesco Tovoli, Maria Aurelia Barbera, et al.
Journal of Hepatocellular Carcinoma|September 13, 2023
Immune-Based Combination Therapies for Advanced Hepatocellular CarcinomaRiccardo Carloni, Simone Sabbioni, Alessandro Rizzo, et al.
Future Oncology (London, England)|April 21, 2021
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic reviewAlessandro Rizzo, Veronica Mollica, Filippo Gustavo Dall'Olio, et al.
Immunotherapy|March 23, 2023
Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?Angela Dalia Ricci, Rosalba D'Alessandro, Alessandro Rizzo, et al.
Drug Design, Development and Therapy|December 22, 2025
Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-AnalysisElsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Anti-Cancer Drugs|August 18, 2021
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinomaGiovanni Brandi, Alessandro Di Federico, Alessandro Rizzo, et al.
Expert Opinion on Drug Safety|November 25, 2022
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysisAlessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, et al.
Cancers|July 24, 2021
Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not EnoughVeronica Mollica, Stefano Brocchi, Filippo Gustavo Dall'Olio, et al.
Annals of Diagnostic Pathology|February 11, 2026
LEF1 and IL13RA2 in testicular sex cord-stromal tumors: LEF1 as a potential diagnostic marker for Sertoli cell tumorsMario Della Mura, Joana Sorino, Gerardo Cazzato, et al.
Pageof 39

Showing results (251-260 of 381) with videos related to

Sort By:
Pageof 39
Future Oncology (London, England)|February 3, 2022
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, et al.
Scientific Reports|July 4, 2018
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of conceptStefania De Lorenzo, Francesco Tovoli, Maria Aurelia Barbera, et al.
Journal of Hepatocellular Carcinoma|September 13, 2023
Immune-Based Combination Therapies for Advanced Hepatocellular CarcinomaRiccardo Carloni, Simone Sabbioni, Alessandro Rizzo, et al.
Future Oncology (London, England)|April 21, 2021
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic reviewAlessandro Rizzo, Veronica Mollica, Filippo Gustavo Dall'Olio, et al.
Immunotherapy|March 23, 2023
Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?Angela Dalia Ricci, Rosalba D'Alessandro, Alessandro Rizzo, et al.
Drug Design, Development and Therapy|December 22, 2025
Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-AnalysisElsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Anti-Cancer Drugs|August 18, 2021
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinomaGiovanni Brandi, Alessandro Di Federico, Alessandro Rizzo, et al.
Expert Opinion on Drug Safety|November 25, 2022
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysisAlessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, et al.
Cancers|July 24, 2021
Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not EnoughVeronica Mollica, Stefano Brocchi, Filippo Gustavo Dall'Olio, et al.
Annals of Diagnostic Pathology|February 11, 2026
LEF1 and IL13RA2 in testicular sex cord-stromal tumors: LEF1 as a potential diagnostic marker for Sertoli cell tumorsMario Della Mura, Joana Sorino, Gerardo Cazzato, et al.
Pageof 39